Literature DB >> 9178463

Anthrax post-vaccinal cell-mediated immunity in humans: kinetics pattern.

E Shlyakhov1, E Rubinstein, I Novikov.   

Abstract

Seven groups (2596 subjects) were vaccinated with a human live anthrax vaccine (HLAV) by three different routes (scarification, subcutaneous and aerosol). The vaccinees were tested for anthrax cell-mediated immunity using the "Anthraxin" skin test at 7, 15, 30, 90, 180 and 365 days following vaccination. The kinetic pattern obtained from all groups, shows a significant, five-phased curve: phase I (2-6 days post-vaccination) shows a slow increase in positive Anthraxin skin reactions. Phase II (7-15 days post-vaccination) shows an exponential rise to a maximum at day 15. Phase III (16-30 days post-vaccination) shows a decrease to day 30. Phase IV (31-90 days post-vaccination) leads to a relative restoration of the positive skin reactions. During phase V (91-365 days post-vaccination) there is a continuous decrease in positive Anthraxin skin reactions. The loss of the skin test reaction on day 30 is a characteristic feature of post vaccination anthrax cell-mediated immunity. It may be due to a blockade of macrophages by lethal anthrax toxin released by the multiplying vaccine strain. Epidemiological observations of HLAV protective rates correlate with the phases of the skin reaction kinetics.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9178463     DOI: 10.1016/s0264-410x(96)00286-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

Review 1.  Bacillus anthracis as an agent of bioterrorism: a review emphasizing surgical treatment.

Authors:  Charles E Binkley; Sandro Cinti; Diane M Simeone; Lisa M Colletti
Journal:  Ann Surg       Date:  2002-07       Impact factor: 12.969

Review 2.  Anthrax lethal toxin and the induction of CD4 T cell immunity.

Authors:  Stephanie Ascough; Rebecca J Ingram; Daniel M Altmann
Journal:  Toxins (Basel)       Date:  2012-10-19       Impact factor: 4.546

3.  Inhalational Anthrax.

Authors:  Erwin Kurt Cullamar; Larry I. Lutwick
Journal:  Curr Infect Dis Rep       Date:  2002-06       Impact factor: 3.663

4.  Quantitative Determination of Lethal Toxin Proteins in Culture Supernatant of Human Live Anthrax Vaccine Bacillus anthracis A16R.

Authors:  Xiaodong Zai; Jun Zhang; Ju Liu; Jie Liu; Liangliang Li; Ying Yin; Ling Fu; Junjie Xu; Wei Chen
Journal:  Toxins (Basel)       Date:  2016-02-25       Impact factor: 4.546

5.  A Comparison of the Adaptive Immune Response between Recovered Anthrax Patients and Individuals Receiving Three Different Anthrax Vaccines.

Authors:  Thomas R Laws; Tinatin Kuchuloria; Nazibriola Chitadze; Stephen F Little; Wendy M Webster; Amanda K Debes; Salome Saginadze; Nikoloz Tsertsvadze; Mariam Chubinidze; Robert G Rivard; Shota Tsanava; Edward H Dyson; Andrew J H Simpson; Matthew J Hepburn; Nino Trapaidze
Journal:  PLoS One       Date:  2016-03-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.